Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

MediMab Biotherapeutics Ltd. Logo

 

 

Formed in March 2020 by Dr Ji Eun Lee, MediMab Biotherapeutics Ltd. is a subsidiary of MediMabBio Inc, a South Korea-based biotechnology firm founded by an Oxford graduate. MediMabBio’s discovery platform utilises systems biology to identify significantly improved first-in-class immuno-oncology drugs that can actively target a range of advanced and solid tumours. The company has developed 4 product pipelines of highly promising novel drugs that aim to overcome the current limitations of cancer immunotherapy.

Having raised $3M for pre-series A funding last year, MediMabBio is expected to raise a further $16M next month in Series A funds.

Dr Li Eun Lee commented "The reason we have chosen the BioEscalator as our base is because we believe that it would be a perfect environment for our company to start and grow within the UK.  It provides an excellent environment in terms of growth, flexibility and accessibility to world-class local facilities that are already in place.  Its location is also advantageous for us to interact and collaborate with other leading scientists based in the university, and other related communities and hospitals.  We also appreciate the support we receive from the BioEscalator staff and colleagues."

Community section

Welcome to our new BioEscalator community page, a space to discover a little more about the people and the companies that make up our biotech ecosystem.